RU2016117941A - Фениколовые противобактериальные средства - Google Patents
Фениколовые противобактериальные средства Download PDFInfo
- Publication number
- RU2016117941A RU2016117941A RU2016117941A RU2016117941A RU2016117941A RU 2016117941 A RU2016117941 A RU 2016117941A RU 2016117941 A RU2016117941 A RU 2016117941A RU 2016117941 A RU2016117941 A RU 2016117941A RU 2016117941 A RU2016117941 A RU 2016117941A
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- pyridin
- fluoro
- acetamide
- hydroxy
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- -1 4- (6 - ((S) -1-amino-2-hydroxyethyl) pyridin-3-yl) phenyl Chemical group 0.000 claims 2
- CJGDDRMHSGSVID-HSFDIDPMSA-N 2,2-dichloro-n-[(1r,2s)-3-fluoro-1-hydroxy-1-[4-(6-pyrrolidin-2-ylpyridin-3-yl)phenyl]propan-2-yl]acetamide Chemical compound C1=CC([C@H]([C@@H](CF)NC(=O)C(Cl)Cl)O)=CC=C1C1=CC=C(C2NCCC2)N=C1 CJGDDRMHSGSVID-HSFDIDPMSA-N 0.000 claims 1
- IZHZXZNJHOXVNS-ZYYFHIKCSA-N 2,2-dichloro-n-[(1r,2s)-3-fluoro-1-hydroxy-1-[4-[6-(1-methylsulfonylpyrrolidin-2-yl)pyridin-3-yl]phenyl]propan-2-yl]acetamide Chemical compound CS(=O)(=O)N1CCCC1C1=CC=C(C=2C=CC(=CC=2)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=N1 IZHZXZNJHOXVNS-ZYYFHIKCSA-N 0.000 claims 1
- IJXOROPCDRQUTK-HZPDHXFCSA-N 2,2-dichloro-n-[(1r,2s)-3-fluoro-1-hydroxy-1-[4-[6-(methanesulfonamidomethyl)pyridin-3-yl]phenyl]propan-2-yl]acetamide Chemical compound C1=NC(CNS(=O)(=O)C)=CC=C1C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 IJXOROPCDRQUTK-HZPDHXFCSA-N 0.000 claims 1
- DUTBYDRHZKSUQR-ZWKOTPCHSA-N 2,2-difluoro-n-[(1r,2r)-3-fluoro-1-[4-[6-[(3-fluoropropylamino)methyl]pyridin-3-yl]phenyl]-1-hydroxypropan-2-yl]acetamide Chemical compound C1=CC([C@H]([C@H](CF)NC(=O)C(F)F)O)=CC=C1C1=CC=C(CNCCCF)N=C1 DUTBYDRHZKSUQR-ZWKOTPCHSA-N 0.000 claims 1
- KXMHSADMFQKZIX-VIYFESSGSA-N 2,2-difluoro-n-[(1r,2s)-3-fluoro-1-[4-[6-[1-(2-fluoroethylamino)ethyl]pyridin-3-yl]phenyl]-1-hydroxypropan-2-yl]acetamide Chemical compound C1=NC(C(NCCF)C)=CC=C1C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(F)F)C=C1 KXMHSADMFQKZIX-VIYFESSGSA-N 0.000 claims 1
- IHUZDFPYYYTTPO-HSFDIDPMSA-N 2,2-difluoro-n-[(1r,2s)-3-fluoro-1-hydroxy-1-[4-(6-pyrrolidin-2-ylpyridin-3-yl)phenyl]propan-2-yl]acetamide Chemical compound C1=CC([C@H]([C@@H](CF)NC(=O)C(F)F)O)=CC=C1C1=CC=C(C2NCCC2)N=C1 IHUZDFPYYYTTPO-HSFDIDPMSA-N 0.000 claims 1
- ZPKIFKPMRJCECV-LZVFCHHLSA-N 2,2-difluoro-n-[(1r,2s)-3-fluoro-1-hydroxy-1-[4-[6-(1-morpholin-4-ylethyl)pyridin-3-yl]phenyl]propan-2-yl]acetamide Chemical compound C=1C=C(C=2C=CC(=CC=2)[C@@H](O)[C@@H](CF)NC(=O)C(F)F)C=NC=1C(C)N1CCOCC1 ZPKIFKPMRJCECV-LZVFCHHLSA-N 0.000 claims 1
- DIIAIRBOIHFISJ-YSGDOOFJSA-N 2,2-difluoro-n-[(1r,2s)-3-fluoro-1-hydroxy-1-[4-[6-[1-(methylamino)ethyl]pyridin-3-yl]phenyl]propan-2-yl]acetamide Chemical compound C1=NC(C(C)NC)=CC=C1C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(F)F)C=C1 DIIAIRBOIHFISJ-YSGDOOFJSA-N 0.000 claims 1
- ADXQRXGFSIDISF-ONPVYFPQSA-N N-[(1R,2S)-1-[4-[6-(1-amino-2-hydroxypropyl)pyridin-3-yl]phenyl]-3-fluoro-1-hydroxypropan-2-yl]-2,2-difluoroacetamide Chemical compound NC(C(C)O)C1=CC=C(C=N1)C1=CC=C(C=C1)[C@H]([C@@H](CF)NC(C(F)F)=O)O ADXQRXGFSIDISF-ONPVYFPQSA-N 0.000 claims 1
- XMBXUPXGFUIICI-VNCLPFQGSA-N N-[(1R,2S)-1-[4-[6-(1-aminopropyl)pyridin-3-yl]phenyl]-3-fluoro-1-hydroxypropan-2-yl]-2,2-difluoroacetamide Chemical compound NC(CC)C1=CC=C(C=N1)C1=CC=C(C=C1)[C@H]([C@@H](CF)NC(C(F)F)=O)O XMBXUPXGFUIICI-VNCLPFQGSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 244000144972 livestock Species 0.000 claims 1
- VTLQQLOYRCBDHM-AGBJPPAESA-N n-[(1r,2s)-1-[4-[2-(1-aminoethyl)-1,3-thiazol-5-yl]phenyl]-3-fluoro-1-hydroxypropan-2-yl]-2,2-dichloroacetamide Chemical compound S1C(C(N)C)=NC=C1C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 VTLQQLOYRCBDHM-AGBJPPAESA-N 0.000 claims 1
- QFVSVQBNVWVTMF-OHLWTUOXSA-N n-[(1r,2s)-1-[4-[5-(1-aminoethyl)thiophen-2-yl]phenyl]-3-fluoro-1-hydroxypropan-2-yl]-2,2-dichloroacetamide Chemical compound S1C(C(N)C)=CC=C1C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 QFVSVQBNVWVTMF-OHLWTUOXSA-N 0.000 claims 1
- IAUWZXJTNGKPHY-GRKKQISMSA-N n-[(1r,2s)-1-[4-[6-(1-amino-2,2,2-trifluoroethyl)pyridin-3-yl]phenyl]-3-fluoro-1-hydroxypropan-2-yl]-2,2-difluoroacetamide Chemical compound C1=NC(C(N)C(F)(F)F)=CC=C1C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(F)F)C=C1 IAUWZXJTNGKPHY-GRKKQISMSA-N 0.000 claims 1
- DWLCHOJQARPCIV-VNCLPFQGSA-N n-[(1r,2s)-1-[4-[6-(1-amino-2-cyanoethyl)pyridin-3-yl]phenyl]-3-fluoro-1-hydroxypropan-2-yl]-2,2-difluoroacetamide Chemical compound C1=NC(C(CC#N)N)=CC=C1C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(F)F)C=C1 DWLCHOJQARPCIV-VNCLPFQGSA-N 0.000 claims 1
- FMBXLWKSECFFEX-VNCLPFQGSA-N n-[(1r,2s)-1-[4-[6-(1-amino-2-methoxyethyl)pyridin-3-yl]phenyl]-3-fluoro-1-hydroxypropan-2-yl]-2,2-difluoroacetamide Chemical compound C1=NC(C(N)COC)=CC=C1C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(F)F)C=C1 FMBXLWKSECFFEX-VNCLPFQGSA-N 0.000 claims 1
- KSOGYPMEYYTORU-YVEJMYDXSA-N n-[(1r,2s)-1-[4-[6-(2-amino-1-hydroxypropan-2-yl)pyridin-3-yl]phenyl]-3-fluoro-1-hydroxypropan-2-yl]-2,2-difluoroacetamide Chemical compound C1=NC(C(N)(CO)C)=CC=C1C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(F)F)C=C1 KSOGYPMEYYTORU-YVEJMYDXSA-N 0.000 claims 1
- WJFRZADFFVECLH-GDBMZVCRSA-N n-[(1r,2s)-1-[4-[6-(3-aminooxetan-3-yl)pyridin-3-yl]phenyl]-3-fluoro-1-hydroxypropan-2-yl]-2,2-difluoroacetamide Chemical compound C=1C=C(C=2C=CC(=CC=2)[C@@H](O)[C@@H](CF)NC(=O)C(F)F)C=NC=1C1(N)COC1 WJFRZADFFVECLH-GDBMZVCRSA-N 0.000 claims 1
- WCUGNSPOHCLJPO-YJEKIOLLSA-N n-[(1r,2s)-1-[4-[6-(azetidin-2-yl)pyridin-3-yl]phenyl]-3-fluoro-1-hydroxypropan-2-yl]-2,2-difluoroacetamide Chemical compound C1=CC([C@H]([C@@H](CF)NC(=O)C(F)F)O)=CC=C1C1=CC=C(C2NCC2)N=C1 WCUGNSPOHCLJPO-YJEKIOLLSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
Claims (28)
1. Соединение, выбранное из группы, состоящей из:
2,2-дифтор-N-{(1S,2R)-1-фторметил-2-гидрокси-2-[4-(6-пирролидин-2-ил-пиридин-3-ил)-фенил]-этил}-ацетамида;
2,2-дихлор-N-{(1S,2R)-1-(фторметил)-2-гидрокси-2-[4-(6-пирролидин-2-илпиридин-3-ил)-фенил]-этил}-ацетамида;
N-((1R,2S)-1-(4-(6-((S)-1-амино-2-гидроксиэтил)-пиридин-3-ил)фенил)-3-фтор-1-гидроксипропан-2-ил)-2,2-дифторацетамида;
2,2-дихлор-N-((1R,2S)-3-фтор-1-гидрокси-1-(4-(6-(метилсульфонамидометил)пиридин-3-ил)фенил)пропан-2-ил)ацетамида;
2,2-дихлор-N-((1R,2S)-3-фтор-1-гидрокси-1-(4-(6-(1-(метилсульфонил)пирролидин-2-ил)пиридин-3-ил)фенил)пропан-2-ил)-ацетамида;
2,2-дихлор-N-((1R,2S)-3-фтор-1-гидрокси-1-(4-(6-(1-(метилсульфонамидо)этил)пиридин-3-ил)фенил)пропан-2-ил)ацетамида;
2,2-дифтор-N-((1R,2S)-3-фтор-1-гидрокси-1-(4-(6-(метилсульфонамидометил)пиридин-3-ил)фенил)пропан-2-ил)ацетамида;
2,2-дифтор-N-[(1R,2R)-1-фторметил-2-(4-{6-[(3-фтор-пропиламино)-метил]-пиридин-3-ил}-фенил)-2-гидрокси-этил]-ацетамида;
N-((1S,2R)-2-{4-[6-(1-амино-2,2,2-трифтор-этил)-пиридин-3-ил]-фенил}-1-фторметил-2-гидрокси-этил)-2,2-дифторацетамида;
2,2-дифтор-N-((1S,2R)-1-фторметил-2-гидрокси-2-{4-[6-(1-морфолин-4-ил-этил)-пиридин-3-ил]-фенил}-этил)-ацетамида;
2,2-дифтор-N-((1S,2R)-1-фторметил-2-гидрокси-2-{4-[6-(1-метиламино-этил)-пиридин-3-ил]-фенил}-этил)-ацетамида;
2,2-дифтор-N-[(1S,2R)-2-(4-{6-[1-(2-фтор-этиламино)-этил]-пиридин-3-ил}-фенил)-1-фторметил-2-гидрокси-этил]-ацетамида;
N-((1R,2S)-1-(4-(6-(3-аминооксетан-3-ил)пиридин-3-ил)фенил)-3-фтор-1-гидроксипропан-2-ил)-2,2-дифторацетамида;
2,2-дифтор-N-((1R,2S)-3-фтор-1-гидрокси-1-(4-(6-(1-(метилсульфонамидо)циклопропил)пиридин-3-ил)фенил)пропан-2-ил)ацетамида;
N-((1R,2S)-1-(4-(5-(1-аминоэтил)тиофен-2-ил)фенил)-3-фтор-1-гидроксипропан-2-ил)-2,2-дихлорацетамида;
2,2-дифтор-N-((1R,2S)-3-фтор-1-гидрокси-1-(4-(6-((RS)-1-(метилсульфонамидо)этил)пиридин-3-ил)фенил)пропан-2-ил)ацетамида;
2,2-дифтор-N-((1R,2S)-3-фтор-1-гидрокси-1-(4-(6-(морфолин-3-ил)пиридин-3-ил)фенил)пропан-2-ил)ацетамида;
N-((1R,2S)-1-(4-(6-(1-амино-2-метоксиэтил)-пиридин-3-ил)фенил)-3-фтор-1-гидроксипропан-2-ил)-2,2-дифторацетамида;
N-((1S,2R)-2-{4-[6-(1-амино-2-циано-этил)-пиридин-3-ил]-фенил}-1-фторметил-2-гидрокси-этил)-2,2-дифторацетамида;
N-((1R,2S)-1-(4-(6-(2-амино-1-гидроксипропан-2-ил)пиридин-3-ил)фенил)-3-фтор-1-гидроксипропан-2-ил)-2,2-дифторацетамида;
N-((1R,2S)-1-(4-(2-(1-аминоэтил)тиазол-5-ил)фенил)-3-фтор-1-гидроксипропан-2-ил)-2,2-дихлорацетамида;
N-((1R,2S)-1-(4-(6-(1-аминопропил)пиридин-3-ил)фенил)-3-фтор-1-гидроксипропан-2-ил)-2,2-дифторацетамида;
N-((1R,2S)-1-(4-(6-(амино(циклопропил)метил)пиридин-3-ил)фенил)-3-фтор-1-гидроксипропан-2-ил)-2,2-дифторацетамида;
N-((1R,2S)-1-(4-(6-(1-амино-2-гидроксипропил)пиридин-3-ил)фенил)-3-фтор-1-гидроксипропан-2-ил)-2,2-дифторацетамида; и
N-((1R,2S)-1-(4-(6-(азетидин-2-ил)пиридин-3-ил)фенил)-3-фтор-1-гидроксипропан-2-ил)-2,2-дифторацетамида, его энантиомеры, диастереомеры или фармацевтически приемлемая соль.
2. Фармацевтическая композиция, содержащая соединение по п. 1, его энантиомеры, диастереомеры или фармацевтически приемлемую соль и фармацевтически приемлемый носитель.
3. Способ контролирования или лечения инфекций у домашнего скота, включающий введение нуждающемуся в этом животному терапевтически эффективного количества соединения по п. 1, его энантиомеров, диастереомеров или фармацевтически приемлемой соли.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261607280P | 2012-03-06 | 2012-03-06 | |
US61/607,280 | 2012-03-06 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014135705/04A Division RU2593204C2 (ru) | 2012-03-06 | 2013-03-01 | Фениколовые противобактериальные средства |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2016117941A true RU2016117941A (ru) | 2018-10-25 |
Family
ID=47892021
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014135705/04A RU2593204C2 (ru) | 2012-03-06 | 2013-03-01 | Фениколовые противобактериальные средства |
RU2016117941A RU2016117941A (ru) | 2012-03-06 | 2013-03-01 | Фениколовые противобактериальные средства |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014135705/04A RU2593204C2 (ru) | 2012-03-06 | 2013-03-01 | Фениколовые противобактериальные средства |
Country Status (20)
Country | Link |
---|---|
US (3) | US9073894B2 (ru) |
EP (1) | EP2822934A1 (ru) |
JP (1) | JP5990287B2 (ru) |
KR (1) | KR101656974B1 (ru) |
CN (1) | CN104271561A (ru) |
AR (1) | AR092306A1 (ru) |
AU (1) | AU2013230499B2 (ru) |
BR (1) | BR112014022214A2 (ru) |
CA (2) | CA2930081A1 (ru) |
CL (1) | CL2014002348A1 (ru) |
CO (1) | CO7071128A2 (ru) |
HK (1) | HK1206028A1 (ru) |
MX (1) | MX2014010724A (ru) |
NZ (1) | NZ630099A (ru) |
PH (2) | PH12014501991A1 (ru) |
RU (2) | RU2593204C2 (ru) |
TW (2) | TWI554500B (ru) |
UA (1) | UA110436C2 (ru) |
WO (1) | WO2013134061A1 (ru) |
ZA (1) | ZA201406477B (ru) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA110436C2 (en) * | 2012-03-06 | 2015-12-25 | Zoetis Llc | Antibacterial phenol compounds |
JP2015532279A (ja) * | 2012-09-26 | 2015-11-09 | ゾエティス・エルエルシー | フェニコール抗菌剤 |
WO2015138934A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
US9790219B2 (en) | 2014-03-13 | 2017-10-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
EP3157917B1 (en) | 2014-06-19 | 2020-03-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
WO2016105468A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
WO2016105477A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
WO2016105484A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
AU2016297886B2 (en) | 2015-07-24 | 2020-12-10 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing CFTR activity |
CA3000483C (en) | 2015-10-06 | 2024-02-13 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
EP3440057B1 (en) | 2016-04-07 | 2021-09-22 | Proteostasis Therapeutics, Inc. | Silicone atoms containing ivacaftor analogues |
MA45397A (fr) | 2016-06-21 | 2019-04-24 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
CN108276405A (zh) * | 2018-03-12 | 2018-07-13 | 南安市创培电子科技有限公司 | 一种医药中间体咪唑并[1,2-a]吡啶-2-羧酸乙酯的合成工艺 |
GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
CN112752748A (zh) * | 2018-09-24 | 2021-05-04 | 硕腾服务有限责任公司 | 用于制备化合物2,2-二氟-n-((1r,2s)-3-氟-1-羟基-1-(4-(6-(s-甲基磺亚胺酰基)吡啶-3-基)苯基)丙-2-基)乙酰胺的方法 |
GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1649829A (zh) * | 2002-03-08 | 2005-08-03 | 先灵-普劳有限公司 | 新型氟苯尼考类抗生素 |
US6790867B2 (en) * | 2002-05-20 | 2004-09-14 | Schering-Plough Animal Health Corporation | Compositions and method for treating infection in cattle and swine |
US8119667B2 (en) * | 2005-12-29 | 2012-02-21 | Schering-Plough Animal Health Corporation | Carbonates of fenicol antibiotics |
CA2829993A1 (en) * | 2011-03-15 | 2012-09-20 | Rib-X Pharmaceuticals, Inc. | Antimicrobial agents |
UA110436C2 (en) * | 2012-03-06 | 2015-12-25 | Zoetis Llc | Antibacterial phenol compounds |
-
2013
- 2013-01-03 UA UAA201409660A patent/UA110436C2/uk unknown
- 2013-03-01 EP EP13710219.0A patent/EP2822934A1/en not_active Withdrawn
- 2013-03-01 AU AU2013230499A patent/AU2013230499B2/en not_active Ceased
- 2013-03-01 CA CA2930081A patent/CA2930081A1/en not_active Abandoned
- 2013-03-01 CA CA2866354A patent/CA2866354C/en not_active Expired - Fee Related
- 2013-03-01 MX MX2014010724A patent/MX2014010724A/es not_active Application Discontinuation
- 2013-03-01 RU RU2014135705/04A patent/RU2593204C2/ru not_active IP Right Cessation
- 2013-03-01 KR KR1020147027930A patent/KR101656974B1/ko active IP Right Grant
- 2013-03-01 JP JP2014560958A patent/JP5990287B2/ja not_active Expired - Fee Related
- 2013-03-01 WO PCT/US2013/028554 patent/WO2013134061A1/en active Application Filing
- 2013-03-01 BR BR112014022214A patent/BR112014022214A2/pt not_active IP Right Cessation
- 2013-03-01 CN CN201380023268.0A patent/CN104271561A/zh active Pending
- 2013-03-01 RU RU2016117941A patent/RU2016117941A/ru not_active Application Discontinuation
- 2013-03-01 NZ NZ630099A patent/NZ630099A/en not_active IP Right Cessation
- 2013-03-05 US US13/785,422 patent/US9073894B2/en not_active Expired - Fee Related
- 2013-03-05 TW TW104131805A patent/TWI554500B/zh not_active IP Right Cessation
- 2013-03-05 TW TW102107673A patent/TWI558694B/zh not_active IP Right Cessation
- 2013-03-05 AR ARP130100730A patent/AR092306A1/es unknown
-
2014
- 2014-09-03 ZA ZA2014/06477A patent/ZA201406477B/en unknown
- 2014-09-04 CL CL2014002348A patent/CL2014002348A1/es unknown
- 2014-09-05 PH PH12014501991A patent/PH12014501991A1/en unknown
- 2014-09-08 CO CO14198156A patent/CO7071128A2/es unknown
-
2015
- 2015-06-05 US US14/731,650 patent/US9340564B2/en not_active Expired - Fee Related
- 2015-07-14 HK HK15106690.3A patent/HK1206028A1/xx unknown
- 2015-07-21 PH PH12015501609A patent/PH12015501609A1/en unknown
-
2016
- 2016-03-16 US US15/071,597 patent/US9428528B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016117941A (ru) | Фениколовые противобактериальные средства | |
PE20151091A1 (es) | Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes | |
IL264982B (en) | Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors | |
RU2460730C2 (ru) | Новые производные n-(8-гетероарилтетрагидронафталин-2-ил)-или n-(5-гетероарилхроман-3-ил)-карбоксамида для лечения боли | |
RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
CL2015001257A1 (es) | Compuestos derivados de 3-(3-(3,5-bis(trifluorometil)fenil)-1h-1,2,4-triazol-1-il)-hidrazida; composicion farmaceutica; procedimiento para preprar precursores; procedimiento para tratar; uso para tratar trastornos asociados a crm1 tal como trastorno proliferativo, inflamatorio, entre otros (divisional de solicitud n° 225-2014). | |
RU2016133626A (ru) | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера | |
RU2014132884A (ru) | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний | |
RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
PE20191555A1 (es) | Agentes inductores de la apoptosis para tratar el cancer y enfermedades inmunes y autoinmunes | |
PE20121354A1 (es) | Inhibidores del virus de la hepatitis c | |
PE20140836A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
PE20130221A1 (es) | Agentes inductores de apoptosis para el tratamiento del cancer y de enfermedades inmunes y autoinmunes | |
HRP20200141T1 (hr) | Derivati piperidina kao gpr119 agonisti | |
UY30906A1 (es) | Productos farmaceuticos comprendiendo primer ingrediente activo n-[2-(dietilamino)-n-(2-{[2-(4-hidroxi-2-oxo-2,3-dihidro-1,3-benziotazol-7-il)etil)-3-[2-(1-nafti)etoxi]propanamida o una sal y un segundo seleccionado de un grupo especifico | |
PE20141421A1 (es) | 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
JP2013527202A5 (ru) | ||
JP2013543896A5 (ru) | ||
JP2009506039A5 (ru) | ||
RU2015123499A (ru) | Соединения замещенной триазолбороновой кислоты | |
RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
PE20141067A1 (es) | Compuestos para el tratamiento de la adiccion | |
RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
RU2017145929A (ru) | МОДУЛЯТОРЫ ROR ГАММА(RORγ) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20190513 |